Avalo Therapeutics (AVTX) Cash from Investing Activities (2016 - 2026)

Avalo Therapeutics has reported Cash from Investing Activities for 11 years, with the latest figure at $25.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities changed N/A year-over-year to $25.5 million; the trailing twelve-month figure through Mar 2026 stood at -$56.2 million (changed N/A YoY), and the FY2025 full-year result was -$81.7 million, down 23055.06% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $25.5 million, up from $2.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $25.5 million in Q1 2026, with the low at -$70.9 million in Q2 2025.
• Historically, Cash from Investing Activities has averaged -$7.0 million across 5 years, with a median of -$47500.0 in 2022.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 51.85% — and 2024, when it surged 367.67%.
• Avalo Therapeutics' Cash from Investing Activities stood at -$39000.0 in 2022, then plunged by 241.03% to -$133000.0 in 2023, then surged by 367.67% to $356000.0 in 2024, then surged by 574.44% to $2.4 million in 2025, then surged by 962.27% to $25.5 million in 2026.
• The last three Cash from Investing Activities figures came in at $25.5 million (Q1 2026), $2.4 million (Q4 2025), and -$13.3 million (Q3 2025), per Business Quant data.